Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10021)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Feb 14, 2016 (publication date) through Dec 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Broder MS, Chang E, Romanus D, Cherepanov D, Neary MP. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. World J Gastroenterol 2016; 22(6): 2118-2125 [PMID: 26877616 DOI: 10.3748/wjg.v22.i6.2118] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i6/2118.htm |
| Number | Citing Articles |
| 1 |
L. M. Tchoumba Tchoumi, M. L. Nchouwet, S. L. Poualeu Kamani, W. Yousseu Nana, R. C. Douho Djimeli, A. Kamanyi, S. L. Wansi Ngnokam. Antimicrobial and antidiarrhoeal activities of aqueous and methanolic extracts of Mangifera indica Linn stem bark (Anarcadiaceae) in Wistar rats. Advances in Traditional Medicine 2021; 21(3): 485 doi: 10.1007/s13596-020-00470-6
|
| 2 |
Lehar Khanna, Thorvardur R. Halfdanarson, Mohamad B. Sonbol, Rachel Eiring, Teresa Prond, Michael Camilleri. Bile Acid Malabsorption in Patients with Neuroendocrine Tumors. Digestive Diseases and Sciences 2022; 67(6): 2517 doi: 10.1007/s10620-021-07189-7
|
| 3 |
V. N. Joish, F. Frech, P. Lapuerta. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. Journal of Medical Economics 2018; 21(2): 182 doi: 10.1080/13696998.2017.1387120
|
| 4 |
Arvind Dasari, Vijay N. Joish, Raul Perez-Olle, Sam Dharba, Kavitha Balaji, Daniel M. Halperin. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Review of Pharmacoeconomics & Outcomes Research 2020; 20(5): 507 doi: 10.1080/14737167.2019.1660646
|
| 5 |
Boniface Pone Kamdem, Brice Rostan Pinlap, Bijou-Lafortune Noumboue Kouamou, Aubin Youbi Kamche, Boris Arnaud Kuate, Joseph Tsemeugne, Orleans Ngomo, Pierre Mkounga, Fabrice Fekam Boyom. Repurposing Synthetic Acetaminophen Derivatives Containing a Benzothiazole Scaffold as an Alternative Therapy for Infectious Diarrhea Caused by Drug-Resistant Shigella Species. Future Pharmacology 2024; 4(2): 420 doi: 10.3390/futurepharmacol4020023
|
| 6 |
M.E. Pavel, E. Baudin, K.E. Öberg, J.D. Hainsworth, M. Voi, N. Rouyrre, M. Peeters, D.J. Gross, J.C. Yao. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Annals of Oncology 2017; 28(7): 1569 doi: 10.1093/annonc/mdx193
|
| 7 |
Julie Hallet, C. H. L. Law, M. Cheung, N. Mittmann, N. Liu, H. D. Fischer, S. Singh. Patterns and Drivers of Costs for Neuroendocrine Tumor Care: A Comparative Population-Based Analysis. Annals of Surgical Oncology 2017; 24(11): 3312 doi: 10.1245/s10434-017-5986-0
|
| 8 |
Tanya Burton, Pablo Lapuerta. Economic Analysis of Inadequate Symptom Control in Carcinoid Cyndrome in the United States. Future Oncology 2018; 14(23): 2361 doi: 10.2217/fon-2018-0129
|
| 9 |
Matthew H Kulke, Hagen F Kennecke, Kris Murali, Vijay N Joish. Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study. Cancer Management and Research 2021; : 7439 doi: 10.2147/CMAR.S330429
|
| 10 |
Boris G. Naraev, Magnus Halland, Daniel M. Halperin, Amy J. Purvis, Thomas M. O'Dorisio, Thorvardur R. Halfdanarson. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas 2019; 48(8): 961 doi: 10.1097/MPA.0000000000001384
|
| 11 |
Arvind Dasari, Vijay N Joish, Raul Perez-Olle, Samyukta Dharba, Kavitha Balaji, Daniel M Halperin. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World Journal of Gastroenterology 2019; 25(47): 6857-6865 doi: 10.3748/wjg.v25.i47.6857
|
| 12 |
Yue Cheng, Lowell Anthony, Chris Delcher, Daniela C Moga, Aman Chauhan, Bin Huang, Val Adams. Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors. The Oncologist 2023; 28(6): 479 doi: 10.1093/oncolo/oyad057
|
| 13 |
Marine Perrier, Charbel Mouawad, Delphine Gueguen, Benoit Thomé, Maryse Lapeyre-Mestre, Thomas Walter. Health care resource use and costs among patients with carcinoid syndrome in France: Analysis of the National Health Insurance Database. Clinics and Research in Hepatology and Gastroenterology 2023; 47(7): 102177 doi: 10.1016/j.clinre.2023.102177
|
| 14 |
Jonathan Strosberg, Vijay N. Joish, Susan Giacalone, Raul Perez-Olle, Ann Fish-Steagall, Kanika Kapoor, Sam Dharba, Pablo Lapuerta, Al B. Benson. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. The Oncologist 2019; 24(11): 1446 doi: 10.1634/theoncologist.2018-0921
|
| 15 |
Al B. Benson, Jonathan Strosberg, Vijay N. Joish, Samyukta Dharba, Dipa Sapre, Pablo Lapuerta. Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency. Pancreas 2020; 49(3): 408 doi: 10.1097/MPA.0000000000001496
|
| 16 |
Lynn Huynh, Todor Totev, Francis Vekeman, Maureen P. Neary, Mei S. Duh, Al B. Benson. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. Journal of Medical Economics 2017; 20(9): 945 doi: 10.1080/13696998.2017.1337019
|
| 17 |
Lowell B. Anthony, Thomas M. O'Dorisio. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. The Oncologist 2021; 26(7): e1171 doi: 10.1002/onco.13847
|
| 18 |
I-Wen Pan, Daniel M. Halperin, Bumyang Kim, James C. Yao, Ya-Chen Tina Shih. A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. PharmacoEconomics 2021; 39(11): 1271 doi: 10.1007/s40273-021-01071-0
|
| 19 |
Tetsuhide Ito, Lingaku Lee, Robert T. Jensen. Carcinoid-syndrome: recent advances, current status and controversies. Current Opinion in Endocrinology, Diabetes & Obesity 2018; 25(1): 22 doi: 10.1097/MED.0000000000000376
|
| 20 |
Enrique Grande, Ángel Díaz, Carlos López, Javier Munarriz, Juan-José Reina, Ruth Vera, Beatriz Bernárdez, Javier Aller, Jaume Capdevila, Rocio Garcia-Carbonero, Paula Jimenez Fonseca, Marta Trapero-Bertran. Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Therapeutic Advances in Endocrinology and Metabolism 2019; 10 doi: 10.1177/2042018819828217
|
| 21 |
Louisa G. Gordon, Thomas M. Elliott, Kate Wakelin, Simone Leyden, John Leyden, Michael Michael, Nick Pavlakis, Jan Mumford, Eva Segelov, David K. Wyld. The Economic Impact on Australian Patients with Neuroendocrine Tumours. The Patient - Patient-Centered Outcomes Research 2020; 13(3): 363 doi: 10.1007/s40271-020-00412-z
|
| 22 |
Michel Archange Fokam Tagne, Paul Aimé Noubissi, Gaëtan Olivier Fankem, René Kamgang. Effects ofOxalis barrelieriL. (Oxalidaceae) aqueous extract on diarrhea induced byShigella dysenteriaetype 1 in rats. Health Science Reports 2018; 1(2) doi: 10.1002/hsr2.20
|
| 23 |
Joseph S Dillon, Chandrikha Chandrasekharan. Telotristat Ethyl: A Novel Agent for the Therapy of Carcinoid Syndrome Diarrhea. Future Oncology 2018; 14(12): 1155 doi: 10.2217/fon-2017-0340
|
| 24 |
Vijay N. Joish, Feride Frech, Pablo Lapuerta. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective. Clinical Therapeutics 2017; 39(12): 2338 doi: 10.1016/j.clinthera.2017.10.019
|
| 25 |
A. Custodio, P. Jimenez-Fonseca, A. Carmona-Bayonas, M. J. Gomez, M. I. Del Olmo-García, I. Lorenzo, J. Á. Díaz, N. Canal, G. De la Cruz, C. Villabona. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clinical and Translational Oncology 2021; 23(10): 2046 doi: 10.1007/s12094-021-02608-7
|
| 26 |
Kira Oleinikov, Shani Avniel-Polak, David J. Gross, Simona Grozinsky-Glasberg. Carcinoid Syndrome: Updates and Review of Current Therapy. Current Treatment Options in Oncology 2019; 20(9) doi: 10.1007/s11864-019-0671-0
|
| 27 |
Kelly Fust, Michael Maschio, Michele Kohli, Simron Singh, D. Mark Pritchard, Florence Marteau, Peter Myrenfors, Marion Feuilly. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. PharmacoEconomics 2020; 38(6): 607 doi: 10.1007/s40273-020-00896-5
|
| 28 |
Dieter Hörsch, Lowell Anthony, David J. Gross, Juan W. Valle, Staffan Welin, Marta Benavent, Martyn Caplin, Marianne Pavel, Emily Bergsland, Kjell Öberg, Kenneth B. Kassler-Taub, Polina Binder, Phillip Banks, Pablo Lapuerta, Matthew H. Kulke. Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study. Neuroendocrinology 2022; 112(3): 298 doi: 10.1159/000516958
|